{"id":916239,"date":"2025-12-04T08:06:09","date_gmt":"2025-12-04T13:06:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/"},"modified":"2025-12-04T08:06:09","modified_gmt":"2025-12-04T13:06:09","slug":"lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/","title":{"rendered":"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Dec.  04, 2025  (GLOBE NEWSWIRE) &#8212; Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, \u201cA Clinician\u2019s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,\u201d at the 22<sup>nd<\/sup> Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9<sup>th<\/sup> at 3 PM ET.<\/p>\n<p>The session will feature a discussion with Dr. Victoria Parikh, M.D., who is Associate Professor of Cardiovascular Medicine at Stanford University and Director of the Stanford Center for Inherited Cardiovascular Disease, and an expert clinician scientist who cares for people living with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors can join the live event by registering on the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OTUVxQTDldzchk5PWaFwf_V6emRP60f1HVwyYv8_fM1lY-A7l86jZwelzFNsY1B5KR1bhblEG41JpVrYjk2eTx7wMxn5kGkRrWl4NmEV5R5oUHnagHu59H5JEkQRoOdYsJf717LDXbuUs4IW2J73hHajP6d0m25DEQkS8pWhgteX_QOt86ltJlSZi4QYMtkU1D1-RHkWCg-5wcrwJf4QaPRZ5eDoTAYAr73ojkUQQ1mUUXtWoNYSo1-pNSOhT-53ztkDvMe88UoDZO_NkDMRhek1DJznw2uJxYcOjXs_eqPKyWlmruYqg5lb6OxumdKxv9Yqd_A-usl97ozO7Y_ApnbGbeUwIlnbrvtwCyPUP9IkdcF7qzXH1B0EfTdeayY7CdkklqLdCqvWOLc2Lqa_RuiSmihkR5lnq7AhPYLf5fd2w_WfAdlZu2f60aiHfcXVqekwdxUP84QWxLA8PF9Ifjoo6IptcHwHUeIBdrzf2utIJd-IglTX99arlmi4b_aBsrZfCwamg72SUcOdk09gGw==\" rel=\"nofollow\" target=\"_blank\">News &amp; Events<\/a>\u00a0page on Lexeo\u2019s website. A replay will be archived on the investor section of Lexeo\u2019s website following the event.<\/p>\n<p>\n        <strong>About Lexeo Therapeutics<\/strong><br \/>\n        <br \/>Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA), LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.<\/p>\n<p>\n        <strong>Media Response:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_3rbA2Fv_GweKSpAi8Kril88-7NLLcM1leA0v3lHALJWSubnXr0fdeGkw1cKCVZs4ARalzJwLjHi0zXO9xl4PFMtf4nIKUvsGvc2nVh91-k=\" rel=\"nofollow\" target=\"_blank\">Media@lexeotx.com<\/a>\n      <\/p>\n<p>\n        <strong>Investor Response:<\/strong><br \/>\n        <br \/>Carlo Tanzi, Ph.D.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=b3uc6h6uhy59p3HkvrLtxINMrrobR8igZOFmGjOp8EEiiqESeLs0Ag0Tr8wjxcP_p9fvNzKgSCq8MaajwKby2js36gyxnWGBN5ADrAtKMuk=\" rel=\"nofollow\" target=\"_blank\">ctanzi@kendallir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODNlZDdhMWEtNzRkYS00ZDdhLWExNTUtNmJkNWU0NTNiZDI3LTEyNDQ3MzktMjAyNS0xMi0wNC1lbg==\/tiny\/Lexeo-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) &#8212; Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, \u201cA Clinician\u2019s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,\u201d at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9th at 3 PM ET. The session will feature a discussion with Dr. Victoria Parikh, M.D., who is Associate Professor of Cardiovascular Medicine at Stanford University and Director of the Stanford Center for Inherited Cardiovascular Disease, and an expert clinician scientist who cares for people living with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors can join the live event by registering on the\u00a0News &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-916239","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) &#8212; Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, \u201cA Clinician\u2019s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,\u201d at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9th at 3 PM ET. The session will feature a discussion with Dr. Victoria Parikh, M.D., who is Associate Professor of Cardiovascular Medicine at Stanford University and Director of the Stanford Center for Inherited Cardiovascular Disease, and an expert clinician scientist who cares for people living with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors can join the live event by registering on the\u00a0News &hellip; Continue reading &quot;Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T13:06:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum\",\"datePublished\":\"2025-12-04T13:06:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/\"},\"wordCount\":250,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/\",\"name\":\"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY=\",\"datePublished\":\"2025-12-04T13:06:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/","og_locale":"en_US","og_type":"article","og_title":"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum - Market Newsdesk","og_description":"NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) &#8212; Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, \u201cA Clinician\u2019s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,\u201d at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9th at 3 PM ET. The session will feature a discussion with Dr. Victoria Parikh, M.D., who is Associate Professor of Cardiovascular Medicine at Stanford University and Director of the Stanford Center for Inherited Cardiovascular Disease, and an expert clinician scientist who cares for people living with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors can join the live event by registering on the\u00a0News &hellip; Continue reading \"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-04T13:06:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum","datePublished":"2025-12-04T13:06:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/"},"wordCount":250,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/","name":"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY=","datePublished":"2025-12-04T13:06:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5NjgyNSM3MzA1MzIwIzIyMzMxODY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexeo-therapeutics-to-host-virtual-key-opinion-leader-event-at-the-22nd-global-cardiovascular-clinical-trialists-cvct-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global\u00a0Cardiovascular Clinical\u00a0Trialists (CVCT) Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/916239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=916239"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/916239\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=916239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=916239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=916239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}